SK Biopharmaceuticals Partners with ProEn Therapeutics to Expand Radiopharmaceutical Oncology Pipeline, Dec. 16, 2024
SK Biopharmaceuticals has partnered with ProEn Therapeutics to advance oncology research and expand its radiopharmaceutical therapy (RPT) pipeline. The collaboration aims to develop up to two preclinical candidates by 2027, leveraging ProEn's ArtBody™ platform to enhance tumor selectivity and minimize damage to healthy tissues. This aligns with SK Biopharmaceuticals' strategic "RPT Roadmap" and builds on previous global partnerships to secure a leading position in nuclear medicine.
Full Article: SK Biopharmaceuticals Collaboration News
NeoPhore Appoints Michael Shih as CEO Following Series B Funding, Dec. 16, 2024
NeoPhore Limited has appointed Michael Shih as Chief Executive Officer and Board member, following its oversubscribed Series B financing round. Shih brings extensive experience in business development at Kite Pharma, Biogen, and Sanofi, which will support the advancement of NeoPhore’s innovative pipeline of small molecule drugs targeting the MMR pathway to enhance cancer immunotherapy efficacy and durability.
Full Article: NeoPhore CEO Announcement
Incyclix Bio Reports Promising Interim Results for Phase I/II INX-315 Trial, Dec. 16, 2024
Incyclix Bio announced promising interim results from the Phase I/II INX-315-01 trial evaluating its CDK2 inhibitor, INX-315, in advanced/metastatic cancers, including ER+/HER2- breast cancer and CCNE1-amplified solid tumors. INX-315 demonstrated a favorable safety profile, with no treatment discontinuations due to adverse events, and notable antitumor activity: 10% partial response rate and 63% stable disease among heavily pretreated participants. CEO Patrick Roberts highlighted its best-in-class potential for resistant cancer types.
Full Article: Incyclix Bio Trial Results
Akamis Bio Secures $60M in Series A Prime Funding and Strategic Partnership with Xuanzhu Biopharma, Dec. 17, 2024
Akamis Bio announced $60 million in Series A Prime funding led by Sedgwick Yard and a partnership with Xuanzhu Biopharma to develop NG-350A, a CD40 agonist gene therapy for solid tumors. The funding will advance NG-350A through a Phase 1b proof-of-concept study in locally advanced rectal cancer. Xuanzhu gains Greater China rights under a licensing deal including upfront payments, milestones, and royalties.
Full Article: Akamis Bio Funding Announcement
Actuate Therapeutics Highlights Positive Phase 2 Data for Elraglusib in Metastatic Pancreatic Cancer, Dec. 17, 2024
Actuate Therapeutics reported positive interim results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma (mPDAC). The combination significantly improved 1-year survival (43.6% vs. 22.5%; p=0.002) and median overall survival (9.3 vs. 7.2 months; HR=0.63) with a favorable safety profile. Phase 3 registration trials are planned for 2025.
Full Article: Actuate Therapeutics Trial Results
BiPER Therapeutics Raises $839K in Bridge Funding Ahead of Series A Round, Dec. 17, 2024
BiPER Therapeutics announced €800,000 ($839K) in bridge financing to support regulatory toxicology studies for its BiP inhibitor, BPR001-615, targeting BiP-positive gastrointestinal cancers. This funding precedes a €30M Series A round aimed at launching Phase 1/2a clinical trials by Q3 2025 to address unmet gastric cancer treatment needs.
Full Article: BiPER Therapeutics Funding News
Spago Nanomedical Doses Second Patient Group in Phase I/IIa Tumorad-01 Study, Dec. 18, 2024
Spago Nanomedical has successfully dosed all patients in the second group of its Phase I/IIa Tumorad-01 study, evaluating 177Lu-SN201 for safety, tolerability, and initial efficacy in cancer treatment. Six patients across five tumor types have been treated, and the Data Monitoring Committee will provide its analysis in Q1 2024. The therapy uses tumor-selective nanotechnology and lutetium-177, showing potential as a broad-spectrum radionuclide therapy. CEO Mats Hansen expressed optimism about the study's progress and its potential to enhance cancer care.
Full Article: Spago Nanomedical Clinical Trial Update
Anaveon Appoints Dr. Richard Sachse as Chief Medical Officer, Dec. 18, 2024
Anaveon has appointed Dr. Richard Sachse as Chief Medical Officer, effective February 1, 2025. Dr. Sachse, formerly CMO at SOTIO Biotech, brings over 25 years of experience in clinical development and regulatory affairs. He succeeds Dr. Eduard Gasal, who was instrumental in advancing Anaveon's lead program, ANV600, to clinical trials. CEO Andreas Katopodis emphasized Dr. Sachse's expertise will be crucial in progressing Anaveon's pipeline of selective cytokine receptor agonists designed to enhance immune response against tumors.
Full Article: Anaveon Leadership Change
Radiopharm Theranostics Receives Approval for Phase 1 HEAT Trial, Dec. 20, 2024
Radiopharm Theranostics has received HREC approval in Australia to initiate the Phase 1 First-In-Human (FIH) HEAT trial of 177Lu-RAD202, a radiotherapeutic targeting HER2-expressing solid tumors, including breast cancer. The trial will assess RAD202's safety and preliminary efficacy. Preclinical studies demonstrated promising results, indicating its potential to address unmet needs in HER2-positive metastatic cancer. CEO Riccardo Canevari highlighted the therapy's promise in improving patient outcomes while preserving quality of life.
Full Article: Radiopharm Theranostics HEAT Trial Approval
Syncromune Raises $100M in Series A to Support mCRPC Trial, Dec. 20, 2024
Syncromune has raised $100 million in Series A funding to support a Phase 2a trial for SV-102, targeting metastatic castration-resistant prostate cancer (mCRPC). The biotech employs a unique approach to freeze tumors and expose antigens, enabling T cells to attack. The funding was led by an undisclosed institutional investor, alongside Wasatch Equity Partners. CEO Eamonn Hobbs will lead the company as it advances this next-generation cancer immunotherapy.
Full Article: Syncromune Series A Investment
Verismo Therapeutics Completes Merger with HLB Innovation, Dec. 20, 2024
Verismo Therapeutics has completed a merger with HLB Innovation (KOSDAQ: 024850), becoming a subsidiary of South Korea's HLB Group. This merger will accelerate the clinical development of Verismo's SynKIR™ CAR therapies for solid tumors and blood cancers. CEO Bryan Kim emphasized that the merger will strengthen resources and capabilities, advancing the company's innovative pipeline within HLB's bio-ecosystem.
Full Article: Verismo Therapeutics Merger
Ottimo Pharma Secures $140M in Series A Funding, Dec. 20, 2024
Ottimo Pharma has raised over $140 million in Series A funding to advance its bifunctional cancer therapies. The funds will support Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for solid tumors, along with a pipeline of follow-on assets. The funding round was led by OrbiMed, Avoro Capital, and Samsara BioCapital. CEO David Epstein will guide the company through this critical phase of clinical development with a strengthened leadership team.
Full Article: Ottimo Pharma Series A Funding
